Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs TCMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: VVOS 1 – 5 TCMD Matrix Metrics: VVOS 1 – 9 TCMD

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin).

  • Growth vs. Quality Trade-Off: TCMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.1/100 SELL vs. VVOS 36.4/100 SELL) and 0.95β · 52% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TCMD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs TCMD
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$25.60
-1.5% 1D
Market Cap $582.2M
TTM Revenue $356M
Forward P/E 17.4x
Beta / 30D Vol 0.95β · 52% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 37.0 Fund 44.0 Flow 65.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 54
RSI-14: 53.6 · SMA20: $25.49 · SMA50: $23.76

6-Pillar Scorecard Institutional Category Breakdown (VVOS 1 – 5 TCMD)

Columns: Metric · VVOS · TCMD
1. Valuation Multiples TCMD
Forward P/E N/M 17.4x
Trailing P/E N/M 25.2x
PEG Ratio N/M 17.79x
EV / Revenue 0.1x 1.5x
2. Growth & Scale VVOS
Revenue Growth (YoY) +34.9% +7.1%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $21M $356M
Market Cap $1.9M $582.2M
3. Profitability & Quality TCMD
Gross Margin 61.9% 77.0%
Operating Margin -107.9% 9.4%
Net Profit Margin -121.8% 6.7%
Return on Equity (ROE) -8585.3% 11.0%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) -$21M EBITDA $29M
Cash Flow Margin -99.3% EBITDA Mgn 8.1%
Net Cash / Leverage -8585.3% ROE $58M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity N/A 67.6% of Rev ($241M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (1) vs TCMD (9)
Institutional Metric VVOS TCMD Criterion Row Edge
Market Capitalization
Scale
$1.9M $582.2M Larger Scale TCMD
Trailing P/E Ratio
Valuation
N/M 25.2x Lower Multiple TCMD
Forward P/E Ratio
Valuation
N/M 17.4x Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+34.9% +7.1% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% 9.4% Higher Margin TCMD
Net Profit Margin
Profitability
-121.8% 6.7% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
-8585.3% 11.0% Higher ROE TCMD
52-Week Range Position
Momentum
0% ($0–$3) 29% ($21–$38) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 0.95β · 52% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite TCMD
Trailing 12M Revenue (USD)
Operating Scale
$21M $356M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev 17.79x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) $29M ($58M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +68.0 pp
VVOS: -59.25% · TCMD: +8.75%
3M Horizon TCMD +90.08 pp
VVOS: -80.49% · TCMD: +9.59%
6M Horizon TCMD +93.96 pp
VVOS: -91.15% · TCMD: +2.81%
1Y Horizon TCMD +103.36 pp
VVOS: -97.71% · TCMD: +5.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue TCMD Revenue VVOS Op. Margin TCMD Op. Margin Margin Leader
FY2018 N/A $140M N/A 2.1% TCMD
FY2019 $10M $190M -92.8% 5.5% TCMD
FY2020 $10M $190M -92.1% -1.9% TCMD
FY2021 $20M $210M -120.7% -0.8% TCMD
FY2022 $20M $250M -156.2% -5.2% TCMD
FY2023 $10M $270M -125.3% 6.6% TCMD
FY2024 $20M $290M -74.3% 7.6% TCMD
FY2025 $20M $330M -114.1% 8.9% TCMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCMD CONSOLIDATION
98d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $582.2M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs TCMD Key Questions & Quantitative Answers

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin). Growth vs. Quality Trade-Off: TCMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.1/100 SELL vs. VVOS 36.4/100 SELL) and 0.95β · 52% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although TCMD compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TCMD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VVOS cumulative revenue shifted +100.0% while TCMD shifted +135.7%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.

TCMD screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas TCMD trades at 17.4x Forward P/E, 25.2x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus TCMD (11.0% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.95β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.